LLY vs ZBIO · P/E 39, rev $22.97B vs rev $10.0M
Eli Lilly and Company (LLY) versus Zenas BioPharma, Inc. Common Stock (ZBIO) — a side-by-side from cached financials, not a winner call.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David A. Ricks.
Zenas BioPharma, Inc. Common Stock (ZBIO) is a biotechnology company listed on US.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Latest reported ZBIO revenue for 2025-12-31 was $10.0M. Net income was -$377.7M. Revenue was up 100.0% from 2024-12-31 to 2025-12-31. ZBIO currently screens at market cap $798.0M.
LLY currently screens at market cap $991.62B and trailing P/E 39.5. ZBIO currently screens at market cap $798.0M.
Not investment advice. Open the LLY and ZBIO stock pages for the full models.
Not investment advice.